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Powell Perng* and Michael Lim
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The central nervous system (CNS) possesses powerful local and global immunosup-
pressive capabilities that modulate unwanted inflammatory reactions in nervous tissue. 
These same immune-modulatory mechanisms are also co-opted by malignant brain 
tumors and pose a formidable challenge to brain tumor immunotherapy. Routes by 
which malignant gliomas coordinate immunosuppression include the mechanical and 
functional barriers of the CNS; immunosuppressive cytokines and catabolites; immune 
checkpoint molecules; tumor-infiltrating immune cells; and suppressor immune cells. 
The challenges to overcoming tumor-induced immunosuppression, however, are not 
unique to the brain, and several analogous immunosuppressive mechanisms also exist 
for primary tumors outside of the CNS. Ultimately, the immune responses in the CNS 
are linked and complementary to immune processes in the periphery, and advances in 
tumor immunotherapy in peripheral sites may therefore illuminate novel approaches to 
brain tumor immunotherapy, and vice versa.
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Part i: introduction
Contrary to common perceptions of central nervous system (CNS) “immune privilege,” the brain can 
in fact elicit vigorous immune-stimulatory as well as immunosuppressive responses, the determinants 
of which are highly contextual. Understanding the determinants and mechanisms of both the stimula-
tory and suppressive responses may help elucidate novel immune-based strategies for brain tumor 
immunotherapy. In this review, we will discuss routes of glioma-mediated immunosuppression, 
including mechanical and functional barriers of the CNS, immunosuppressive cytokines, immune 
checkpoint molecules, tumor-infiltrating immune cells, and suppressor immune cells (Table 1). In 
addition, we will look to analogous immune-modulatory mechanisms observed in other sites of the 
body, as discoveries made at CNS and non-CNS sites are ultimately complementary and equally 
relevant to therapeutic development for tumors at all sites (1).
Part ii: The CNS immune environment
The notion of “immune privilege” has long been ascribed to tissues wherein the immunological 
responsiveness is ostensibly blunted or modified (122). Early experimental observations that the 
brain lacked traditional lymphatic systems, contained few, if any, professional antigen-presenting 
cells (APCs), and mounted anemic immune responses against foreign antigens bolstered the theory 
that the brain was an “immunologically privileged” tissue. It is now apparent that the CNS is in fact 
capable of coordinating robust immune responses with the innate and adaptive immune systems, 
TABLe 1 | Key examples of immune-modulatory mechanisms shared between malignant gliomas and non-CNS tumors.
Malignant gliomas Non-CNS tumor
TUMOR ANTiGeN PReSeNTATiON
Antigen-presenting cells Glioma-associated microglia and/or macrophages (2–4);  
DCs (5); B lymphocytes (6); possibly pericytes (7)
DCs (8–11); tumor-associated macrophages (12–14); B 
lymphocytes (6); possibly pericytes (7)
Location of antigen presentation Brain parenchyma and/or tumor mass (2–4); tumor-draining 
lymph nodes (15–17)
Tumor-draining lymph nodes (18–20); tumor mass (21)
Routes of antigen egress from 
tumor
Fluid drainage (22, 23); migrating DCs less likely (24–27) Migrating DCs (28–30) and/or fluid drainage (31)
iMMUNOSUPPReSSive CYTOKiNeS
IL-10
Sources Glioma-associated macrophages and microglia (32) Tumor cells (33, 34) and/or tumor-associated macrophages (35)
Actions Immunosuppression (various) (36, 37); context-dependent  
pro-inflammatory and anti-tumor actions (38, 39)
Immunosuppression (various) (40); anti-angiogenesis (41), anti-
metastatic (41), anti-tumor (42–44); anti-inflammatory (45)
TGF-β
Sources Glioma cells (46–48) and glioma-associated immune cells (49) Tumor cells and tumor-associated immune cells (49–51)
Actions Immunosuppression (various) (52); angiogenesis (53); 
maintains glioma stem cell populations (54); glioma cell 
autocrine proliferation (55); pro-invasion (56)
Immunosuppression (various) (50, 57, 58); tumor suppression 
(50, 57–59)
iNDOLAMiNe 2,3-DiOXYGeNASe (iDO)
Sources Glioma cells and tumor-associated immune cells (60–62) Tumor cells, tumor-associated immune cells, and endothelial 
cells (62–65)
Actions Immunosuppression (various) (66); expansion of Treg 
population (67, 68)
Immunosuppression (various) (66); expansion of Treg population 
(67, 68)
ReGULATORY T LYMPHOCYTeS
Predominant Treg type nTreg (69) more than iTreg nTreg more than iTreg (70)
Relevant Treg recruitment factors CCL22 (71–73), CCL2 (71, 74, 75) CCL2, CCL22 (76–81), CCL17 (81); CCL3, CCL4 (82); CCL5 (83)
TUMOR-ASSOCiATeD MYeLOiD CeLLS
Types Microglia (84, 85), macrophages (86), MDSCs (87) Macrophages (88), MDSCs (89, 90)
Actions Immunosuppression (various) (91–95); tumor invasion (96); 
tumor proliferation (97, 98)
Immunosuppression (various) (99); tumor invasion (100); tumor 
proliferation (100)
PD-1/PD-L1 iMMUNe CHeCKPOiNT
Sources Glioma cells (101); microglia (102); glioma-associated 
macrophages (103); neurons in tumor-adjacent brain 
tissue (104)
Tumor cells (105–109), tumor-associated macrophages (100, 
110, 111); healthy tissue (112–114)
Relevant signaling pathways PI3K/mTOR (101) PI3K/mTOR (106, 108, 115, 116), MyD88/TRAF6 (117), MEK/
ERK (117)
Actions Immunosuppression, esp. via T cell suppression (118, 119); 
induction of glioma cell death (104)
Immunosuppression, esp. via T cell suppression (120, 121)
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and that the immunological reactivity of the CNS is a mutable 
rather than an absolute state. Moreover, several of the structural 
and functional immunoregulatory features of the CNS that aid 
in dampening local immune responses are also reflected within 
other organs of the body. Therefore, the traditional notion of CNS 
“immune privilege” has become an imprecise characterization of 
the CNS immune environment, which is a more rightfully a highly 
contextual rather than an absolutely impregnable system.
Reframing the CNS immune environment
In recent decades, the consensus view of the CNS immune 
environment has shifted from one in which the blood–brain 
barrier (BBB) serves as a static barrier against the exchange of 
cells and soluble molecules into one in which egress and entry are 
dynamically regulated, often by mechanisms observed in other 
organ systems. During inflammation, immune cells migrate into 
the CNS parenchyma following dynamic gradients of chemotactic 
cues, including IFN-γ inducible cytokines (123, 124), α and β 
integrins (125), and matrix metalloproteinases (126), which also 
play key roles in leukocyte trafficking in peripheral tissues (127). 
Similarly, it has been postulated that soluble immune effectors, 
such as immunoglobulins (128), might also cross the BBB. One 
possibility is by way of carrier-mediated transporters (129, 130). 
For example, FcRn, a ubiquitous immunoglobulin receptor 
expressed by a wide variety of tissues, can mediate Ig transport 
across tissue barriers (131, 132). Although the routes by which Igs 
enter the CNS parenchyma is yet unknown, it has been postulated 
that FcRn, which is highly expressed on cerebral vessels (131), 
may play a key role in facilitating Ig entry into the CNS, as in 
other tissues (133).
Whereas the absence of traditional lymphatic systems was once 
heralded as evidence that the CNS was immunologically inert (134), 
it is now abundantly clear that soluble antigens routinely egress the 
CNS and reach the peripheral lymph nodes. In vivo tracer studies 
have demonstrated that CNS antigens drain via cerebrospinal fluid 
across the cribiform plate and into the nasal sub-mucosa (135). 
A separate pathway by which antigens travel to the cervical lymph 
nodes (CLNs) via the Virchow–Robin perivascular spaces within 
walls of the cerebral arteries has also been described (22, 23). 
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Indeed, during homeostatic conditions, antigens from the CNS 
are continuously sampled by DCs in the peripheral lymph nodes 
in the same fashion as antigens that arise from other sites (15). 
A more thorough discussion regarding antigen presentation in 
the CNS and peripheral tissues is provided in the next section of 
this review.
Lastly, although the entirety of CNS is often presumed to share 
the same immunological features, the relative absence of immune 
cells under homeostatic conditions is more accurately an attribute 
of the CNS parenchyma proper (127). At resting state, CSF-
drained spaces, including the choroid plexus, leptomeninges, 
ventricles, and perivascular spaces, contain professional APCs 
and respond to foreign antigens in the same manner as organs do 
outside of the CNS (127, 136). By comparison, the parenchyma 
proper is generally devoid of peripheral immune cells and is 
maintained in a quiescent state by mechanical obstacles of the 
endothelial BBB (127). Obstacles against leukocyte entry include 
the CSF-drained Virchow–Robin perivascular space situated 
behind the endothelium, as well as the glia limitans, a wall of pali-
sading astrocyte foot processes located between the perivascular 
space and CNS parenchyma (137). Aside from forming a second 
mechanical barrier against immune cells, the foot processes also 
express death ligand FasL/CD95L (138), which induces apoptosis 
in Fas-expressing T cells and arrests the inflammatory process. 
Accordingly, the vast majority of inflammatory cells that cross 
into the Virchow–Robin spaces during homeostatic states are 
retained in the perivascular space and never proceed past the 
glia limitans (127, 139). Inflammation and disease, however, can 
compromise the integrity of the BBB, thereby permitting circu-
lating immune cells to infiltrate the parenchyma in significant 
numbers (136).
Hence, although the precise mechanisms underlying how 
and when the CNS coordinates immune responses remain to 
be clarified, there is accumulating evidence that several of the 
immunoregulatory features observed in the brain are shared by 
other tissues in the body as well. Baseline FasL expression, for 
example, is not unique to cerebral astrocytes but is also a feature in 
multiple peripheral tissues where immune homeostasis is favored, 
including lymphoid tissue, hepatocytes, testis, striated muscle, as 
well as certain glandular tissues (140–142). Blood–tissue barriers 
formed by intercellular tight junctions exist in the testis as they 
do in the CNS, and multiple organs, including the brain, liver, and 
gastrointestinal tract, secrete immune-modulatory cytokines that 
increase regulatory T cell expression and induce local immune 
tolerance (122). Therapeutic developments designed to overcome 
the immune-regulatory mechanisms of the BBB may therefore 
arise from discoveries made in the brain as well as findings made 
at other sites.
Part iii: Tumor Antigen Presentation
Classically, extracellular antigens are captured at the cell surface, 
endocytosed, and presented on MHC class II molecules to CD4+ 
T-lymphocytes by specialized APCs (143). By comparison, endog-
enous antigens are processed in the rough endoplasmic reticulum 
of nearly all cell types and subsequently presented on MHC class 
I molecules to CD8+ T lymphocytes (144). Presentation of 
tumor antigens, however, is thought to involve a third process, 
termed “cross-presentation,” whereby exogenous tumor antigens, 
scavenged from dying tumor cells, are presented on MHC Class I 
molecules to CD8+ T-lymphocytes, thereby directing the adaptive 
immune response toward malignant cells (145).
In peripheral sites, activation of tumor antigen-specific T 
cells is believed to take place within secondary lymphoid tissue, 
mediated by bone marrow-derived DCs via cross-presentation 
(145). Far less is known, however, regarding the process of prim-
ing T-cells against CNS tumor antigens (146). In particular, it 
remains unclear whether the anti-tumor immune response is 
initiated locally within the brain or peripherally in the body. The 
provenances of these processes have clear implications for brain 
tumor immunotherapies, such as dendritic cell-based vaccines 
(147, 148), that aim to exploit tumor antigen presentation to 
augment tumor immunity.
Tumor Antigen Presentation: CNS
Whether CNS tumor antigen presentation occurs within the brain 
or outside of it remains unclear, though the presence of APCs 
within the brain supports the hypothesis that presentation begins 
locally. Because of their strategic position behind the BBB and their 
essential role in CNS innate immunity, microglia are often charged 
with being the primary APCs for intracranial antigen presentation. 
The data show that microglia have the capacity to cross-present 
tumor antigens to CD8+ T cells via MHC class I in vitro (2–4) and 
in vivo (2, 4). Employing a murine model in which whole-body 
radiation was used to eliminate peripheral and CNS-associated 
APCs (e.g., DCs and macrophages in the perivascular spaces), 
Jarry et al. recently demonstrated that microglia could successfully 
cross-present intra-cerebrally injected OVA antigen to naïve CD8+ 
T cells in vivo (4), strengthening prior data (2).
Tumor-infiltrating DCs may also play a key role in glioma 
antigen presentation (146). The data indicate that DCs cross-
present OVA antigen more efficiently than adult microglia, eliciting 
greater quantities of IL-2 and IFN-γ production from CD8+ T 
cells than microglia (2). Similarly, Jarry et al. reported that CD8+ 
T cell activation was more efficient in non-irradiated mice, which 
contained CNS-associated DCs along with microglia, than in 
irradiated mice, which contained solely microglia (4). Especially 
given that flow-cytometry (FACS) markers used to identify DCs 
lack the specificity necessary for distinguishing between DCs and 
activated microglia (5), APC activity may be falsely attributed to 
microglia in many cases.
Whether microglia and tumor-infiltrating DCs can successfully 
activate CD8+ T cells in the setting of malignant brain tumors, 
however, is uncertain. Current data suggest that microglia lose 
their capacity to express MHC molecules in the context of 
high-grade gliomas (3, 149, 150), likely due to the high levels of 
immunosuppressive cytokines, such as TGF-β, IL-10, and PGE2, 
within the glioma microenvironment (151, 152). Even after remov-
ing microglia from the glioma environment, the ability for the 
microglia to upregulate MHC expression following stimulation 
was substantially depressed compared to normal brain microglia 
(153). Moreover, in the presence of glioma cells, microglial pro-
duction of pro-inflammatory cytokine TNF-α is suppressed by as 
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much as 50% compared to normal microglia, and activation of 
STAT3 transcription factor and secretion of immunosuppressive 
IL-10, both of which modulate immunosuppression, are greatly 
upregulated (154). Similarly, IL-10 has also been shown to inhibit 
DC maturation and maintain DCs in a tolerogenic state (155). 
These data suggest that malignant gliomas may skew APCs toward 
immunosuppressive phenotypes and hinder effective tumor 
antigen presentation within the brain. In vivo tumor models are 
needed to assess whether the APC capacities of microglia and 
DCs are in fact compromised in the glioma parenchyma and 
microenvironment.
Aside from microglia and DCs, tumor-associated macrophages 
(TAMs), B lymphocytes, and vascular pericytes may provide other 
cellular sources for CNS tumor antigen presentation. TAMs, which 
infiltrate gliomas in large numbers and possess cross-presentation 
capabilities (156), are thought to actually outnumber microglia 
(86) within the tumor mass. With regard to antigen-presentation 
capacity, data from a murine model of multiple sclerosis suggest 
that, compared to microglia, CNS-infiltrating macrophages are 
more highly activated and stimulate greater T cell proliferation 
in vitro (157). To our knowledge, however, no study to date has 
explicitly compared tumor antigen cross-presentation capacity of 
microglia to TAMs, likely due to limitations in reliably distin-
guishing microglia from TAMs within gliomas (158). Given that 
microglia and TAMs can both be polarized toward immunosup-
pressive M2-like phenotypes by the same sets of glioma-derived 
cytokines (159), it is possible that antigen-presenting capacity of 
microglia and TAMs are similarly impaired by the immunosup-
pressive glioma microenvironment.
B cells, which can function as efficient APCs outside of the 
CNS (6), are also believed to play a vital role in tumor antigen 
presentation in gliomas. Using a murine glioma model along 
with separate adenoviral vectors (Ad) encoding herpes simplex 
virus type I thymidine kinase (Ad-TK) and fms-like tyrosine 
kinase 3 ligand (Ad-Flt3L), which were used to kill tumor cells 
and recruit APCs to the microenvironment, Candolfi et  al. 
showed that treatment with Ad-TK  +  Ad-Flt3L produced 
long-term survivors in 60% of WT mice but 0% in B-cell 
depleted mice (160). Moreover, when Ad-TK + Ad-Flt3L was 
administered to mice lacking transcriptional repressor Blimp-1, 
the absence of which causes arrest of terminal differentiation of 
B cells into antibody-producing plasma cells, Blimp-1-negative 
mice produced identical numbers of long-term survivors as 
WT mice, suggesting that tumor regression occurred irrespec-
tive of whether anti-tumor antibodies were generated (160). 
Lastly, in Ad-TK +  Ad-flt3L-treated mice, the accumulation 
of antigen-bearing activated B cells within tumor-draining 
lymph nodes (TDLNs) along with evidence that the activated 
B cells were capable of stimulating CD8+ T cell proliferation 
in vitro were strong clues that B cells can cross-prime CD8+ 
T cells against glioma antigens and thereby orchestrate glioma 
regression (160).
Pericytes, which are perivascular cells that classically modulate 
blood flow, vessel permeability, and vessel remodeling at arterioles, 
venules, and capillaries, have also been shown to possess phagocyte 
and antigen-presentation capacity (7). Indeed, Peiper et al. recently 
reported that brain capillary pericytes, which are exquisitely 
sensitive to inflammatory cytokines, increase phagocytic activ-
ity and MHC class II expression when stimulated by TNF-α or 
IFN-γ (161). Key questions surrounding whether pericytes posses 
cross-presentation capacity and how the glioma microenviron-
ment influences pericyte antigen-presentation ability remain to be 
answered. There are data from non-CNS tumor models, however, 
that suggest tumor-derived vascular pericytes may play an overall 
immunosuppressive role, and APC activity may therefore be 
impaired (162).
Interestingly, recent work by Thompson et al. illuminated that 
priming and differentiation of naïve CD8+ T cells can occur within 
tumor masses, irrespective of intratumoral APCs or TDLNs (21). 
It has been shown that prolonged TCR stimulation in the absence 
of CD28 co-stimulation might alone be sufficient for activating 
T cells (163), and high densities of tumor antigens within tumor 
masses may thereby provide a prolonged and powerful enough of 
a stimulus to activate T cells irrespective of APCs (21). Although 
these specific experiments involved melanoma tumors in non-CNS 
sites, there is also evidence that brain tumors themselves support 
terminal differentiation of CD8+ T cells (164). Therefore, the 
findings by Thompson et al. may yet find parallels in malignant 
brain tumors.
It is also possible, however, that presentation of brain tumor 
antigens occurs within peripheral lymphoid tissues outside of 
the CNS (16). Routes by which CNS antigens drain to the nasal 
mucosa and CLNs via CSF and/or perivascular spaces have been 
well described (22, 23), and recent evidence indicates that CNS 
antigens are continuously sampled in peripheral lymphoid tissue 
by DCs (15). Using intra-cerebral (IC) injections of fluorescent 
microspheres and OVA antigen in a mouse model, Walter et al. 
showed (1) that IC antigens preferentially accumulated in CLNs, 
and (2) that expansion of OVA-specific CD8+ T cells occurred 
within CLNs 2 days prior to their appearance in the brain, suggest-
ing that cross-presentation occurs in the CLNs and not within the 
brain parenchyma (16). In a separate study, Okamoto et al. showed 
that 2 weeks following cerebral implantation of glioma tumors 
in rats, activated CD4+ and CD8+ T cells appeared exclusively 
within the CLNs, and their accumulation coincided temporally 
with T-cell infiltration into the tumor (17). Collectively, these data 
suggest that presentation of CNS tumor antigens may initiate in 
lymphoid tissue outside of the CNS.
Finally, it is also conceivable that priming the anti-tumor 
immune response involves processes both within and outside of 
the CNS. Transferring pre-activated tumor-specific CD8+ T cells 
into glioma-bearing mice, Masson et al. demonstrated that further 
phenotypic differentiation of tumor-specific CD8+ T cells occurs 
within the tumor mass (164). Compared to the pre-activated tumor-
specific CD8+ T cells, tumor-infiltrating CD8+ T cells showed 
enhanced expression of IFN-γ, granzyme B, and αE(CD103)β7 
integrin, the latter of which was found to be important for T-cell 
retention within the brain (164). Further analysis of human glioma 
tissue revealed similar differentiation patterns, with 20–57% of 
tumor-infiltrating CD8+ T cells expressing αE(CD103)β7 integrin 
compared to fewer than 5% of CD8+ T cells in peripheral blood 
(164). Consistent with that of murine tissue, approximately 60% 
of αE(CD103)β7-expressing CD8+ T cells in human glioma tissue 
also co-expressed granzyme B (164). It has been hypothesized that 
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locally secreted TGF-β, which induces αE(CD103)β7 expression in 
non-CNS sites (165), may also moderate αE(CD103)β7 expression 
on T cells within gliomas (164). Further work is needed to evaluate 
how the glioma microenvironment initiates and/or shapes the 
effector immune response.
Tumor Antigen Presentation: Non-CNS Sites
In comparison to CNS tissues, there is a greater degree of clarity 
regarding the process of tumor antigen presentation in non-CNS 
tissues, though several aspects remain under contention. A pre-
ponderance of data indicate that presentation of tumor antigens 
occurs within the TDLNs, where resident DCs have been shown 
to play the key roles in priming naïve T cells (18–20). Additionally, 
several experiments have demonstrated that resident DCs within 
TDLNs can indeed cross-present tumor antigens to CD8+ T 
cells in vivo (8–10). Though macrophages are also endowed with 
cross-presentation capacities, they are substantially less efficient 
than DCs at priming CD8+ T cells (12–14). In the absence of con-
vincing data supporting the primacy of alternative mechanisms, 
DCs have been presumed as the main APCs for cross-priming 
tumor-directed CTLs at non-CNS sites.
Further investigation, however, is needed to clarify the precise 
roles as well as cross-presentation capacities of DC subsets in 
tumor antigen presentation, as experimental models show that DC 
phenotypes can vary greatly depending on tissue and/or antigen 
type. DCs in murine lung tissue, for example, display CD103+ 
CD11b− and CD103− CD11bhi phenotypes while colonic DCs 
exhibit a predominately CD103−CD11b+ phenotype. Human 
liver harbors myeloid-derived CD1c+ DCs (166) while human 
renal tissue contains a greater portion of lymphoid-derived or 
plasmacytoid DCs (pDCs) than conventional myeloid-derived 
DCs (167). During CNS inflammation, the brain parenchyma is 
heavily infiltrated with DCs displaying CD11c+ phenotypes (18). 
Of note, a recent analysis of three resident DC subsets from human 
tonsil lymphoid tissue demonstrated that all subsets were capable 
of cross-priming CD8+ T cells with high efficiency (11).
Several animal studies have also illustrated that distinct DC 
subsets may mediate antigen presentation depending on type and 
location of antigen exposure (168–173). For example, whereas 
CD8α+ CD11b− DCs mediated cross-presentation of OVA 
antigen in the spleen, CD8α− CD11b+ DCs were responsible for 
OVA cross-presentation in the mesenteric lymph nodes (173). 
Analysis of circulating DCs in patients with NSCLC and breast 
cancer further revealed disparities in the proportion of pDCs to 
conventional myeloid-lineage DCs between the two malignancies, 
suggesting that tumor type may influence DC phenotypes (174). 
Further work is needed to evaluate the roles of phenotypic DC 
subsets in tumor antigen presentation as well as how tumors may 
influence phenotypic differentiation, as these are all important 
considerations for developing tailored immunotherapeutic inter-
ventions for various tumor sites (11).
As with the CNS, B lymphocytes and vascular pericytes may 
also participate in tumor antigen presentation at non-CNS sites. 
In fact, it has been shown that in mice that have been immunized 
against specific protein antigens, CD40 ligand-activated B lym-
phocytes traffic to secondary lymphoid organs and present peptide 
antigens to naïve T cells with comparable efficacy to DCs (175). 
Recently, B lymphocytes pre-loaded with specific tumor antigens 
were used successfully as a source of APCs for tumor eradication 
in an experimental model (176). As with the CNS, pericytes are 
potential sources for perivascular phagocyte activity at non-CNS 
sites (7). Further work is needed to determine whether pericytes 
associated with non-CNS tumors contribute to tumor antigen 
presentation and/or immune evasion.
The manner in which tumor antigens reach TDLNs at non-CNS 
sites also requires further clarification. Traditionally, it has been 
assumed that migrating DCs carry tumor antigens from the tumor 
site to TDLNs, where antigens are then transferred to resident 
DCs for subsequent T-cell priming (28–30). Evidence from viral 
models, wherein DCs carried antigens from the site of injection 
to draining lymph nodes for CTL activation, lent credence to the 
theory (29, 30, 177–179). The need for migrating DCs for antigen 
presentation in peripheral tissues was also a point of distinction 
between non-CNS and CNS tissues, where a preponderance of 
data suggested that intra-parenchymal DCs do not migrate to the 
CLNs in substantial numbers (24–27).
Recent evidence, however, has challenged the role of migrat-
ing DCs in tumor antigen presentation. Findings from several 
studies suggest that the immunosuppressive milieu of the tumor 
microenvironment may in fact hinder DC function and migration 
from peripheral tissues (180–184). IL-10, for example, which is 
produced by a number of tumors, prevents DC maturation and 
suppresses DC antigen-presenting capabilities (185). A recent 
study by McDonnell et  al. reported that cross-presentation of 
tumor antigens within TDLNs was dependent on the continu-
ous drainage of tumor antigens from the tumor site rather than 
DC migration (31), as is the case with CNS tissue. As previously 
discussed, Thompson et al., who described that priming of CTLs 
could occur within tumor masses themselves, raises the possibility 
that DCs altogether may be unnecessary for activating T cells (21). 
The high density of tumor antigens within the tumor parenchyma 
may provide sufficient stimulus for T-cell receptor (TCR) activa-
tion (21). Therefore, the cross-presentation of tumor antigens in 
peripheral tissues may in fact share commonalities with that of 
the CNS.
Antigen Presentation and Therapeutic Implications
In aggregate, these data show that much is still unknown regarding 
whether antigen-specific T cells, directed against CNS tumors, 
are primed locally in the CNS or peripherally in non-CNS sites. 
However, the data do speak strongly to the notion that priming 
tumor-specific T cells may, at least in part, occur within the body, 
emphasizing the need to evaluate anti-tumor immune responses 
directed at CNS tumors within a global context. Whether initial 
tumor antigen presentation occurs in the brain or in the body, for 
example, could have significant design implications for whether 
vaccine-based glioma therapies are designed for intracranial or 
peripheral administration.
Recent progress in evaluating tumor antigen presentation in 
the body has also identified shared features with the CNS. Similar 
to brain, peripheral tissues may also depend upon fluid drainage 
of tumor antigens to TDLNs rather than migrating DCs for the 
purpose of priming tumor-specific T-cells (31). Tumor-associated 
immunosuppressive cytokines, which will be discussed in further 
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detail in subsequent sections of this review, also present barriers 
to APC activity in CNS and non-CNS sites alike. Novel strategies 
aimed at augmenting anti-tumor immune responses at the level of 
tumor antigen presentation may therefore arise from discoveries 
made at both CNS and non-CNS sites. Notably, DC phenotypes 
can also vary greatly depending on tissue type, raising the possibil-
ity that DC-based therapies may ultimately also require tailored 
approaches that account for site-specific tumor biology.
Part iv: immunosuppressive  
Cytokines – iL-10 and TGF-β
Cytokines with powerful immunosuppressive properties, 
including TGF-β and IL-10, are known mediators of tumor 
proliferation, invasion, and immune evasion. As such, targeted 
blockades of immunosuppressive cytokines are an attractive 
approach to tumor immunotherapy both in the brain and the 
body. A major challenge of cytokine-directed immunotherapy, 
however, lies in the pleiotropic and often paradoxical immune-
regulatory functions of these cytokines. Neither TGF-β nor 
IL-10 is purely immunosuppressive and pro-tumorigenic in 
its effects. Therefore, developing successful immunotherapies 
that target immunosuppressive cytokines requires site-specific 
considerations that pay heed to micro-environmental context 
and tissue-specific biology.
interleukin-10
Interleukin-10, arguably the most potent anti-inflammatory 
cytokine (185), is secreted by numerous cell types of the innate 
and adaptive immune system, including APCs and CD4+ 
T-helper cells, as well as malignant tumors of the brain and the 
body (186, 187). T-helper cells, monocytes, macrophages, and 
DCs are particularly important both as targets and actors of 
IL-10-mediated immunosuppression (155). Binding of IL-10 to 
its receptor (IL-10R) on DCs activates STAT3 transcription fac-
tor, which suppresses STAT-dependent signaling of inflammatory 
cytokines, IL-6, TNF-α, and IL-1B (188, 189); upregulates IL-10 
secretion (190); and maintains DCs in an immature, tolerogenic 
state (155, 191). In macrophages, monocytes, and DCs, IL-10 
also suppresses antigen-presenting capabilities by activating 
MARCH1, an E3 ligase that ubiquintinates cell-surface MHC 
Class II molecules for endocytosis and destruction (192, 193). 
IL-10 also hinders cytotoxic T-lymphocyte effector functions by 
inducing and sustaining FoxP3 transcription factor expression in 
immunosuppressive Treg cells (194, 195).
Paradoxically, IL-10 can also exert pro-inflammatory and 
anti-tumor effects (42). In fact, IL-10 gene was first isolated from 
T-cells that also secreted IFN-γ (196), illustrating the complex 
relationship between anti-inflammatory and pro-inflammatory 
response of IL-10. IL-10 is a potent stimulator of NK cells (197), 
mast cells, and B cells, and, often in combination with other 
cytokines, can potentiate cytotoxic activity of CD8+ T cells 
(198–202). IL-10 also exerts important anti-angiogenic effects 
by suppressing cytokine promoters of angiogenesis, which in 
certain pre-clinical tumor models has been shown to inhibit 
tumor growth (41, 203).
To date, investigations into the role of IL-10 in tumor growth has 
largely focused on its immunosuppressive actions. However, both 
immunosuppressive and anti-tumor effects appear to be active 
in tumors at all sites to varying degrees (185), which naturally 
presents challenges for IL-10-directed immunotherapy.
IL-10: Malignant Gliomas
Human gliomas have long been known to produce IL-10 in vivo 
(204). Among subclasses of human astrocyte tumors, the most 
aggressive tumors contained the highest levels of IL-10 mRNA, 
with glioblastoma tissue containing the most of any astrocyte 
tumor (204). Rather than secreting IL-10 directly, however, 
glioma cells produce soluble factors that induce tumor-associated 
macrophages (TAMs) and microglia to secrete the majority of the 
cytokine (32).
Consistent with its immunosuppressive actions elsewhere in 
the body, glioma-associated IL-10 down-regulates MHC class II 
expression on monocytes and inhibits IFN-γ and TNF-α produc-
tion by immune cells (36, 37). IL-10 also upregulates checkpoint 
molecule B7-H1 (PD-L1) on both glioma-associated macrophages 
and circulating monocytes in peripheral blood (103). B7-H1 can 
bind and stimulate PD-1 receptor on activated T cells, producing 
T-cell anergy and apoptosis (118, 205). Furthermore, IL-10 has 
been shown to confer growth advantages to glioma tissues. Ex vivo, 
IL-10 both increases glioma proliferation (206) and confers invasive 
potential to glioma cells in a dose-dependent manner (207).
In conjunction with other cytokines, IL-10 can also facilitate 
anti-glioma immune responses. Mice implanted with gliomas 
expressing both IL-10 and IL-2 had significantly smaller (99% 
smaller) tumor sizes and increased T-cell infiltration at 14 days 
post-implantation compared to mice with IL-10−/IL-2− tumors 
(38). Additionally, this reduction in tumor size could not be 
reproduced with either IL-10 or IL-2 expressing tumors alone (38).
More recently, Vleeschouwer et al. reported that persistent and 
elevated IL-10 production by T-cells was in fact required for T-cell 
suppression of glioma growth following stimulation with tumor 
lysate-loaded dendritic cells (39). Ectopic IL-10 delivery during 
the T-cell stimulation phase further increased the levels of IFN-γ 
production and hindered tumor growth (39). It has been postu-
lated that the complex interplay between IL-10 and IFN-γ might 
regulate the immunosuppressive effect of indolamine 2,3-dioxy-
genase (IDO) tryptophan metabolism by glioma-associated APCs, 
resulting in a stronger anti-tumor immune response (208). The 
role of IDO in glioma-induced immunosuppression is discussed 
in subsequent sections of this review.
IL-10: Non-CNS Tumors
While IL-10 also plays a duplicitous role in tumor suppression and 
progression at tissues outside of the CNS, its biological actions 
in peripheral sites also differ in several important ways. IL-10 
mRNA and protein have been isolated from a variety of human 
tumors, including ovarian (209), breast (203, 210), renal cell (211), 
lung (212), squamous and basal carcinomas (213), and metastatic 
melanoma (33, 214). Unlike gliomas, however, where the vast 
majority of IL-10 is produced by tumor-associated macrophages 
and microglia, several peripheral tumors produce IL-10 directly. 
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For example, metastatic melanoma (33) and bronchogenic car-
cinomas (34) produce IL-10 almost exclusively, with little or no 
secretion by TAMs.
At the same time, other peripheral tumors, similar to gliomas, 
may also rely upon TAMs to produce the majority of IL-10. 
HPV-16 associated carcinomas, for example, have been shown to 
recruit TAMs, which produce the majority of IL-10 (35). Whether 
or not similar soluble factors are utilized by gliomas and systemic 
tumors to induce TAMs to produce IL-10 is still unknown, but 
such knowledge would be therapeutically relevant for targeting 
IL-10 in these tumors.
In certain peripheral tumors, IL-10 also appears to have a par-
ticularly strong stimulatory effect on NK cells (197). In a murine 
B16 melanoma model, ectopic injection of IL-10 into the tumor 
mass reduced the numbers of infiltrating CD8+ and CD4+ T cells 
and macrophages (215), which is consistent with observations 
from gliomas; however, IL-10 also increased infiltration of NK 
cells in melanoma (215), which has not been reported in gliomas. 
Exogenous IL-10 was also shown to inhibit melanoma metastasis in 
mice that were deficient in B cells and T cells but with competent 
NK cells (41), suggesting that infiltrating NK cells may play a key 
role in suppressing metastatic spread.
The anti-angiogenic effects of IL-10 may also play an important 
part in inhibiting tumor growth and metastasis. IL-10 is known to 
suppress the macrophage production of pro-angiogenic cytokines, 
including IL-1, IL-6, IL-8, TNF-α, and MMP-9 (41, 216). Indeed, 
whereas the blood vessels were all but absent in the surrounding 
tissue of IL-10 secreting melanoma tumors, the tissue surround-
ing non-IL-10 producing tumors was highly vascularized (41). 
Whether IL-10 exerts similar anti-angiogenic and anti-metastatic 
effects in CNS tumors is yet unknown, although in vitro data sug-
gest that the pro-proliferative effects of IL-10 in malignant gliomas 
may outweigh the inhibitory effects (206, 207).
Lastly, IL-10 serves a protective role in certain tissues of 
the body where chronic inflammation plays an etiological role 
in cancerogenesis. In these tissues, IL-10 is a key cytokine for 
maintaining anti-inflammatory T-regulatory cells and suppressing 
pro-inflammatory IL-17-expressing Th17 cells (217). Mice that 
were deficient in IL-10 spontaneously developed inflammatory 
bowel disease (IBD), which later progressed to colorectal carci-
noma (43). Likewise, a small human study reported that IL-10 and 
IL-10R deficiencies, which has been linked to early onset IBD (45, 
218), may also be associated with the development of malignant 
lymphomas (44). These pro-tumorogeneic associations become 
particularly important in the context of therapeutic approaches 
that may systemically deplete, or block the effects of, IL-10.
IL-10 in the Brain and Body: Therapeutic Implications
Taken together, these data illustrate the enigmatic role of IL-10-
mediating tumor growth as well as suppression, the balance of which 
is greatly influenced by tumor biology and micro-environmental 
cues. It is particularly interesting that in the setting of malignant 
gliomas, IL-10 derived from TAMs exerts an overall tumorogenic 
and immunosuppressive effect, whereas IL-10 secreted in persis-
tent and high levels by T-cells can produce pro-inflammatory 
and anti-tumor effects. These data indicate that cell of origin of 
IL-10 may determine, at least in part, its phenotypic actions in 
the tumor environment. Specific cell populations may therefore 
be selectively depleted to achieve the desired pro-inflammatory 
or anti-inflammatory effect.
From a therapeutic standpoint, it is also important to elucidate 
how IL-10 might interact with other cytokines in the microenvi-
ronment to generate an anti-tumor or pro-tumor response. IL-2, 
for example, appears to potentiate the anti-tumor response in 
malignant gliomas. In non-CNS tumors, IL-10 has been shown 
to augment CD8+ T-cell cytotoxicity in a manner that is dependent 
on its expression of IFN-γ and granzymes (219). Pegylated IL-10 
(PEG-IL-10), which in pre-clinical tumor models was shown to 
expand tumor-resident CD8+ T cells and mediate tumor rejection 
(217), has entered human trials as monotherapy or in combination 
with chemotherapy for patients with advanced solid tumors, which 
include melanoma, NSCLC, renal cell, colorectal, ovarian, prostate, 
and pancreatic cancers (Clinical Trial NCT02009449) (Bauer 2014 
ASCO). Whether PEG-IL-10 alone or in combination with IL-2 
holds promise for treating malignant gliomas remains to be seen.
TGF-β
TGF-β is a 25-kDa cytokine that is produced by several cell types, 
including both immune cells and malignant tumors (220). TGF-β 
is formed as a pre–pro-polypeptide and is activated through a 
series of protealytic cleavage steps. The active isoforms of TGF-β, 
TGF-B1, TGF-B2, and TGF-B3, signal by bringing together two 
pairs of serine/threonine kinases known as type I and type II TGF-
β receptors (57). Canonically, cross-phosphorylation of type I and 
II receptors leads to downstream phosphorylation of Smad family 
of transcription factors, which migrate to the nucleus and regulate 
transcription of various target genes (57).
TGF-β is highly pleiotropic, regulating a wide array of biologi-
cal functions that include cell proliferation, migration, survival, 
angiogenesis, embryonic stem cell differentiation, and immune 
surveillance (220). Its role in cancer genesis is also manifold, 
serving as a suppressor of early-stage tumor proliferation but an 
abettor of late-stage tumor progression (58). Elevated expression 
of TGF-β and its receptors by several human cancers, both in 
the brain and the body, has been associated with higher tumor 
grade and/or poorer prognosis (221). These malignancies include 
prostate cancer, small cell lung carcinoma, pancreatic cancer, 
gastric cancer, transitional cell carcinoma of the bladder, as well 
as malignant gliomas (221).
TGF-β: Malignant Gliomas
TGF-β was, in fact, initially isolated from the serum of patients 
with malignant gliomas. Fittingly described as a soluble “humoral 
immunosuppressive” factor, glioma-derived TGF-β significantly 
depressed lymphocyte functions and induced systemic lympho-
penia, particularly in CD4+ T helper cell populations (222). 
Subsequent decades of research have further elucidated that TGF-β 
actually depresses cytotoxic functions of all cells of the immune 
system, facilitating immune evasion and glioma growth (52). MHC 
class II expression on glioma cells, macrophages, and microglia, for 
example, are significantly depressed by TGF-β (223). Expression of 
NKG2D activating receptor on the surface of NK cells are likewise 
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reduced, as is production of CD8+ CTL cytolytic gene products 
perforin, granzyme A, granzyme B, FasL, and IFN-γ (224, 225). 
TGF-β also polarizes T-cells and monocyte-lineage cells toward 
immunosuppressive phenotypes, which further perpetuates a 
tolerogenic state that favors tumor growth (57). Moreover, TGF-β 
is believed to facilitate glioma growth and invasion by promoting 
angiogenesis (53), sustaining glioma stem cell populations (54), 
inducing the production of platelet-derived growth factor (PGDF), 
which serves as an autocrine proliferative signal for glioma cells 
(55), as well as increasing the synthesis of pro-invasive matrix 
metalloproteinases (56).
Strategies that block TGF-β signaling have been shown to restore 
anti-tumor immunity in pre-clinical glioma models. For example, 
in vitro silencing of TGF-β1 and TGF-β2 synthesis in human glioma 
cells using small interfering RNA (siRNA) techniques was shown to 
prevent NKG2D down-regulation on NK cells and enhance MICA 
expression on glioma cells (224). Furthermore, siRNA-silenced 
glioma cells displayed increased susceptibility to immune cell 
lysis (224). In a murine glioma model, inhibiting TGF-β1 receptor 
using SX-007, an oral serine/threonine kinase inhibitor, produced 
greater numbers of long-term survivors (33%) in the experimental 
group compared to control group (6%) (226). The treatment group 
receiving SX-007 also had higher levels of CD8+ T-cells in the 
CLNs than control groups, indicating TGF-β blockade can reverse 
its immunosuppressive effects (226). Taken together, these data 
illustrate that TGF-β confers predominately immunosuppressive 
and pro-invasive advantages to malignant gliomas, and blocking 
TGF-β signaling can reverse its malignant effects.
TGF-β: Therapies for Malignant Gliomas
In the brain, modulating TGF-β is particularly attractive. Radiation, 
a therapeutic cornerstone for malignant CNS tumors, has been 
shown to increase TGF-β expression both in  vitro and in  vivo. 
Neutralizing TGF-β might not only counteract the immunosup-
pressive and pro-invasive effects of TGF-β on the tumor but also 
attenuate the radiation-induced activation of TGF-β. Indeed, a 
small-molecule TGF-βR1 kinase inhibitor LY2109761 increased 
radio-sensitivity of GBM cell lines and stem cells in  vitro. In 
combination with radiotherapy, LY2109761 reduced the tumor 
growth and prolonged the survival in ortho-topic intracranial 
murine glioma models compared to radiotherapy alone (227). 
Conceivably, this benefit might also extend to tumors at other 
sites that are frequently treated with radiotherapy, such as prostate 
adenocarcinoma or head-and-neck squamous cell carcinomas.
Several compounds targeting TGF-β signaling in malignant 
gliomas have entered clinical trials (220); their efficacy, however, 
remains inconclusive. One of the most promising compounds was 
Trabedersen, an anti-sense oligonucleotide against TGF-β2 mRNA 
that was shown to inhibit tumor proliferation and enhance anti-
tumor immunity in vitro (228). In phase I/II trials, Trabedersen 
was associated with improved survival in patients with refractory 
high-grade gliomas compared to literature data (229). Although 
a subsequent randomized phase IIb clinical trial of Trabedersen 
reported improved tumor control and trended toward improved 
2-year survival among patients with refractory anaplastic astrocy-
toma compared to chemotherapy (230), the results of the trial have 
been called into question based on several methodological weak-
nesses (231). The Phase III trial of Trabedersen, which was halted 
in 2012 due to patient recruitment issues, was recently terminated 
in light of advances in neurosurgical and first-line standard of care 
for glioblastoma (220). However, phase I and II trials of LY2157299, 
an oral TGF-β receptor kinase inhibitor, for newly diagnosed and 
recurrent glioblastomas have recently completed accrual, and 
efficacy data are expected in 2015 (232–235).
TGF-β: Non-CNS Tumors
Whereas TGF-β exerts predominately immunosuppressive and 
tumorigenic effects in the context of gliomas, its role in influencing 
tumor growth in other sites of the body is arguably more pleio-
tropic and context-dependent, which makes modulating TGF-β 
in systemic tumors exceedingly complex. Neutralizing TGF-β may 
indeed cause tumor regression at sites that depend on TGF-β for 
proliferation but, at the same time, may also inadvertently cause 
tumor growth in tissues where TGF-β serves as a tumor suppressor 
(50). TGF-β, for example, is a potent inhibitor of epithelial cell 
proliferation (236–238), and inactivating mutations of TGF-β 
receptors are implicated in the development of several human 
carcinomas (50). Neutralizing the protective effects of TGF-β could 
conceivably promote malignant transformation of epithelial tissue.
Even among tumors of the same tissue type, inactivating 
mutations of TGF-β and/or its receptor can lead to disparate 
effects. Mutations in TGF-β receptor are frequently found in 
colon cancer (239–242), and mouse models have shown that 
inactivating mutations in the TGF-β gene increases spontane-
ous formation of colorectal carcinoma (243). Yet, paradoxically, 
patients with a form of hereditary colorectal carcinoma, termed 
HNPCC, and who frequently have TGF-β receptor mutations 
actually have better prognoses than patients with sporadic colon 
cancer without TGF-βR mutations (239, 244). Lastly, similar to 
the potential off-target effects of IL-10, whether or not a tumor 
arises in a pro-inflammatory or anti-inflammatory environment 
also becomes a key consideration in modulating TGF-β. Gastric 
adenocarcinomas, for example, which can develop as a result of 
protracted tissue inflammation following H. pylori colonization, 
may flourish in the absence of TGF-β and other immunosuppres-
sive cytokines.
Nevertheless, several strategies for targeting TGF-β in non-
CNS tumors, including anti-sense oligonucleotides, monoclonal 
antibodies, vaccines, and small-molecule inhibitors, have shown 
moderate success in pre-clinical models of breast, colorectal, 
pancreatic, hepatocellular, and renal cell carcinomas, with some 
proceeding toward human trials (220). The efficacy as well as off-
target effects of modulating this multi-faceted cytokine remain 
to be seen.
Part v: indolamine 2,3-Dioxygenase  
1 – Tryptophan Metabolism
Indolamine 2,3-dioxygenase 1 is a cytosolic enzyme produced by 
macrophages and dendritic cells, primarily in response to pro-
inflammatory factors (such as IFN-γ, IFN-α, IFN-β, and LPS) 
(245, 246). IDO catalyzes the rate-limiting step of tryptophan 
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degradation, producing, among other Trp metabolites, kynure-
nine, which exerts several immunosuppressive effects that may 
help to regulate inflammation (66). Most notably, kynurenine 
facilitates expansion of T-reg populations and inhibition of T 
cell effector functions (67, 68). IDO, however, is also expressed 
by several human tumors in the brain and the body, including 
lung, prostate, colorectal, pancreatic, and endometrial cancers, 
as well as glioblastoma multiforme (60, 247). Moreover, level of 
IDO expression by malignant tumors has been correlated with 
poorer prognoses (248), indicating that IDO and the expansion 
of Treg populations may play a critical role in abetting tumors in 
evading host immunity.
iDO: Malignant Gliomas
Indolamine 2,3-dioxygenase 1 is not expressed in the brain under 
normal physiological conditions. IDO mRNA, however, is substan-
tially elevated in human glioma tissues and correlates negatively 
with overall survival (60, 61). Similar to other tumor sites outside 
of the CNS, the malignant effect of IDO on glioma progression 
appears largely to result from IDO-mediated accumulation of 
thymus-derived nTreg cells, which subsequently exert immuno-
suppressive effects on effector cells in the tumor microenvironment 
(60). Specifically, production chemokine CCL22 by glioma cells is 
believed to play a key role in recruiting and trafficking peripheral 
nTregs into the glioma milieu, a subject that is discussed in more 
depth in subsequent sections of this review in Ref. (71, 72).
Recent data also indicate that glioma cells, rather than TAMs, 
microglia, and DCs, directly produce the majority of the IDO 
(60), which is distinct from tumors outside of the CNS where DCs 
account for the majority of tumor-derived IDO (62–65). In a murine 
glioma model where GL261 cells were injected intracranially into 
the brain of WT or IDO-deficient mice, peripheral expression of 
IDO had no impact on intratumoral T-cell accumulation or overall 
survival (60) between the two groups of mice. By comparison, 
implantation of IDO-producing GL261 tumor cells into the same 
set of mice resulted in significantly increased intratumoral Treg 
accumulation and reduced overall survival (60). Interestingly, 
when IDO-expressing and IDO-non-expressing glioma cells 
were implanted concurrently in separate cerebral hemispheres 
within the same mouse, any survival benefit normally attributed 
to IDO-deficient tumors was eliminated by the presence of IDO-
expressing gliomas in the contralateral cerebral hemisphere (249). 
Taken together, these data illustrate that IDO, produced directly by 
glioma cells, globally suppresses the anti-glioma immune response 
by recruiting thymus-derived nTregs.
iDO: Site-Specific Considerations for 
immunotherapy
Although tumors both in the brain and the body can exploit 
IDO-mediated immunosuppression to overcome host anti-tumor 
immune responses, molecular inhibition of IDO activity has pro-
duced different responses in different organs, which may reflect 
unique tissue-specific factors.
In a murine breast tumor model, 1-methyl-tryptophan (1-MT), 
a widely studied inhibitor of IDO, failed to inhibit tumor growth 
(250); however, in combination with cytotoxic chemotherapies, 
including paclitaxel, cisplatin, cyclophosphamide, and doxoru-
bicin, 1-MT produced significant tumor regression (250). The 
synergic effects between cytotoxic chemotherapy and 1-MT 
have also been reported in melanoma models (251). In glioma 
models, however, it appears that, in sufficient doses, 1-MT alone 
can produce significant anti-tumor effects (249). Moreover, when 
co-administered with cytotoxic chemotherapy, 1-MT failed to 
improve survival over chemotherapy alone (249), suggesting that 
the synergism between IDO inhibition and chemotherapy may 
depend on differences in tissue biology between CNS and non-
CNS tumors. It has been postulated, for example, that separate 
tryptophan-metabolizing enzymes, such as IDO2 or TDO, that 
are also known to mediate immunosuppression in gliomas, may 
provide compensatory kynurenine production under states of 
cellular stress (249).
Interestingly, administering 1-MT with anti-CTLA-4 and 
anti-PD-L1 monoclonal antibodies produced a 100% long-term 
survival rate in glioma-bearing mice (249), an improvement over 
the 90% long-term survival rate in anti-CTLA-4 and anti-PD-L1 
therapies alone. By comparison, the same triple therapy regimen 
was dramatically less effective at extending survival in mice with 
intracranially implanted B16 melanoma tumors, illustrating that 
the utility of IDO modulation may differ substantially based on 
tumor type and environmental context (249).
Lastly, differential patterns of IDO expression among tumor 
types may also impact therapeutic efficacy of IDO modulation. 
Recent tissue analysis of 15 human tumor types showed that 
IDO expression was largely restricted to tumor cells, myeloid-
lineage cells, and endothelial cells (62). The distribution of IDO 
expression among the three categories of cells, however, varied 
greatly from tumor to tumor. IDO expression within renal cell 
carcinomas tissue, for example, appeared to be largely restricted to 
the vasculature, whereas IDO expression within colorectal cancer 
tissue appeared to be limited to DCs (62). Whereas cervical tumor 
tended to express IDO on the outer edges of the parenchyma, IDO 
expression in endometrial tumors was more diffusely distributed 
throughout the parenchyma (62). The frequency of IDO expres-
sion also varied depending on tumor type. For example, cervical 
and endometrial carcinomas were found to be most frequently 
IDO+ (83 and 94% of all cervical and endometrial carcinoma 
tissue samples, respectively) while glioblastoma tissues were most 
frequently IDO− (only 8% of glioblastoma tissues were found to 
express IDO) (62). Further work is needed to characterize how 
variable expression patterns of IDO among different tissue types 
may affect IDO-targeted immune-modulation therapy.
Part vi: T-Regulatory Lymphocytes
Regulatory T lymphocytes (Tregs) are a highly diverse and plastic 
subset of CD4+ immunosuppressive helper T cells that play an 
essential role in promoting immunological tolerance (252, 253). 
As guardians against autoimmunity, Tregs can also hamper 
anti-tumor immune responses and facilitate tumor growth, an 
undesired consequence of that has long been recognized (254, 
255). Malignancies both in the brain and body actively recruit and 
sustain Tregs into the tumor microenvironment and parenchyma, 
and numerous studies have correlated higher intratumoral Treg 
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density with higher tumor grades and poorer prognoses (256). 
Hence, Tregs are believed to play a pivotal role in tumor-mediated 
immunosuppression and subsequent immune escape, leading to 
the failure of immune therapies.
Natural and Adaptive Tregs
CD4+ Tregs comprise approximately 5–10% of circulating CD4+ 
T cell population, and, based on developmental origin, Tregs are 
classified as either thymus-derived natural Tregs (nTregs) or 
peripherally induced “adaptive” Tregs (iTregs) (257). Subsets of 
the CD8+ suppressive regulatory T-cells, for which less is known 
about their immunomodulatory roles in disease than CD4+ 
counterparts, also exist and are reviewed elsewhere (253).
nTregs develop in the thymus from CD4+ single-positive 
thymocytes via antigen presentation by thymic epithelial cells 
(257). nTregs characterized by stable and high-level expression of 
Forkhead Box P3 (FoxP3), key transcription factor and regulator 
for Treg development and immunosuppressive function (252). 
Mice and humans with rare FoxP3 gene dysfunctions suffer florid 
autoimmune attack on multiple organs and tissues, culminating in 
a fatal disorder known as immunodysregulation polyendocrinopa-
thy enteropathy X-linked syndrome (IPEX) (258). More recently, 
the transcription factor Helios as well as neuropilin-1, a sema-
phorin III receptor, has also been identified as potential markers 
for nTregs (259–262). Although incompletely characterized, nTregs 
exert their immunosuppressive function in a contact-dependent, 
cytokine-independent mechanisms, which include the expres-
sion of surface molecules CTLA-4 and PD-L1, membrane-bound 
TGF-β, pericellular generation of adenosine, as well as through 
Granzyme B/Perforin and Fas/FasL pathways (49, 263–268).
By comparison, iTregs, which encompass several distinct CD4+ 
T cell types (257), differentiate in the periphery when antigens are 
presented to and recognized by naïve conventional CD4+ T cells 
(Tconv) under tolerogenic conditions. In contrast to nTregs, which 
display constitutive expression of FoxP3, iTreg FoxP3 expression 
is transient or even absent, and its induction appears dependent 
on IL-10 and/or TGF-β signaling (49, 252). iTregs also appear to 
exert their immunosuppressive effects by releasing soluble factors, 
such as IL-10 and TGF-β (49), instead of the cell-surface ligand 
molecules used by nTregs.
Ultimately, whether Tregs are thymically or peripherally 
derived, Tregs are capable of wholesale suppression of innate and 
adaptive effector immune cell function (253). From a therapeutic 
standpoint, however, it is valuable to understand the process by 
which tumor-infiltrating Tregs accumulate within various tumors, 
such that the targeted strategies might be developed to modulate 
specific Treg populations.
Treg Accumulation in Brain
Greater numbers of glioma-associated Tregs has been associated 
with higher tumor grade (269), and levels of tumor-infiltrating 
Tregs may prove to be an important prognostic indictor for survival 
(270), though the data are conflicting (271–273). Based on cur-
rent methods for evaluating Treg phenotype, the data suggest that 
tumor-infiltrating Tregs in malignant gliomas are predominately 
nTregs, rather than iTregs (69). In a murine glioma model, levels 
of tumor-infiltrating Tregs were significantly diminished for mice 
that were thymectomized prior to tumor implantation compared 
to that of non-thymectomized mice (69). In addition, over 90% of 
Tregs within the tumor expressed Helios transcription factor (69), 
which is known to be highly expressed on thymus-derived nTregs 
but not iTegs in mice and humans (262), strengthening the claim 
that glioma-associated Tregs may be nTregs.
The precise mechanism by which gliomas recruit nTregs is still 
under investigation; however, it is becoming evident that gliomas 
produce several soluble factors (72) that aid in recruiting nTregs into 
the microenvironment and parenchyma. In particular, gliomas are 
known to produce CC chemokine ligand 22 (CCL22), which serves 
as a potent chemotactic factor for leukocytes expressing CCL22 
receptor CC chemokine receptor 4 (CCR4). Glioma-infiltrating 
Tregs express particularly high levels of CCR4 compared to other 
tumor-infiltrating lymphocytes (73), and several in vitro migration 
studies have demonstrated the ability of glioma-derived CCL22 to 
induce Treg chemotaxis (71–73).
CC chemokine ligand 2, another chemokine produced by 
human gliomas (74) and a weaker ligand for CCR4, has also 
been implicated in glioma-mediated Treg chemotaxis (71, 75). 
In vitro administration of blocking antibodies to CCR4 as well 
as CCL2 receptor, CCR2, arrested Treg migration toward glioma 
supernatant (71). Whether CCL22 and/or CCL2 are significant 
Treg chemotactic factors in vivo is still a matter of contention (71, 
72, 75); however, it is evident that other soluble factors within the 
glioma microenvironment also contribute to Treg chemotaxis, and 
these factors remain to be identified (72).
Interestingly, outside of the tumor parenchyma and microen-
vironment, circulating CCL22 appears to be depressed in the sera 
of patients with malignant gliomas (274). Additionally, in a serum 
analysis of 1,208 patients with glioma, one group recently reported 
that lower serum levels of CCL22 were a negative prognostic 
indictor for overall survival (274). Because gliomas are known to 
exert global immunosuppressive effects, the lower levels of CCL22 
in sera seen in patients with higher grade gliomas compared to 
lower grade gliomas was thought to reflect glioma-mediated sup-
pression of peripheral APCs, which are the predominant producers 
of CCL22 in  vitro and in  vivo (275). The precise mechanisms 
underlying this relationship, however, remain to be elucidated. 
Further clarification is needed regarding whether glioma-related 
production of CCL22 is related to levels of CCL22 in peripheral 
blood, as well as whether glioma-derived CCL22 is also associated 
with disease prognosis.
Though iTregs may likely play a lesser role in glioma immu-
noresistance (69), there is reason to believe that gliomas are also 
capable of converting Tconv into iTregs in vivo. TGF-β and IL-10, 
both of which are produced by gliomas in vivo, have been shown 
to induce Treg conversion in vitro (252, 276). Prostaglandin E2, 
which is also produced by gliomas via cyclo-oxygenase 2 (COX-2), 
can induce de novo Tconv to Treg conversion (277, 278).
Treg Accumulation at Non-CNS Sites
Whether tumor-infiltrating Tregs in peripheral sites are 
thymus-derived or peripherally induced Tregs is also con-
troversial, especially in the absence of definitive markers for 
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distinguishing nTregs from iTregs (257). There is compelling 
evidence, however, that intratumoral Tregs from non-CNS 
sites also comprised predominately nTregs rather than iTregs, 
similar to the distribution in malignant gliomas. Using a mouse 
fibrosarcoma tumor model, Waight et al. recently demonstrated 
that intratumoral Tregs bore CpG hypomethylation at FoxP3 
Treg-specific demethylated region (TSDR) (70), which is 
thought to be an epigenetic hallmark for nTregs (279). Moreover, 
epigenetic analysis of intratumoral Tregs from human NSCLC 
and ovarian tumors revealed demethylation at the FoxP3 TSDR 
similar to that observed in murine tumor models, suggesting 
that tumor-infiltrating Tregs in human tumors may also be 
nTregs (70). Whether similar distributions of Treg subtypes 
based on epigenetic markers are found in other peripheral 
tumors remains to be determined.
Similar to gliomas, several non-CNS tumors, including ovarian 
(76), breast (77), prostate (78), gastric (79), esophageal (80), as 
well as Hodgkin lymphoma (81) tumor cells can also elaborate 
CCL22 to help recruit Tregs into the tumor microenvironment. 
Notably, in one recent study of 417 cases of invasive breast cancer, 
high tumor expression of CCL22 was associated with higher 
histological grade and greater density of tumor-infiltrating Tregs 
(280). Furthermore, higher CCL22 expression was reported to be 
an adverse predictor of progression-free and overall survival (280). 
Higher ratio of stromal CCR4+ Tregs to CD8+ Tregs was also 
negatively associated with overall survival in human oral squamous 
cell carcinoma (OSCC) (281), indicating a potential relationship 
between CCL22 and overall survival in OSCC.
At the same time, Treg chemoattractant profiles can also vary 
greatly from tumor to tumor in peripheral sites. For instance, 
CCL17, another ligand to CCR4, does not appear to play a role 
in Treg chemotaxis in glioma or ovarian carcinoma but is a key 
mediator in Hodgkin’s lymphoma and gastric adenocarcinoma 
(81). In colorectal carcinoma, TAMs secreting CCL20 attracted 
tumor-infiltrating Tregs that highly expressed CC chemokine 
receptor 6 (282). Likewise, in an experimental melanoma model, 
tumor-infiltrating Tregs expressed CCR5 and preferentially 
migrated toward its ligands CCL3, CCL4, and CCL5, which were 
elaborated by tumor-infiltrating myeloid-derived suppressor cells 
(MDSCs) (82). Similarly, CCR5–CCL5 signaling also appears to 
play a prominent role in Treg migration in both human and murine 
pancreatic adenocarcinoma (83).
Though, as with the brain, the most recent data suggest 
that the majority of tumor-infiltrating Tregs in peripheral sites 
are also nTregs, non-CNS tumors can also elaborate TGF-β, 
IL-10, and PGE2, which can induce peripheral iTreg conver-
sion. Administration of anti-TGF-β antibody in  vitro blocked 
conversion of Tconv to the Treg phenotype, and in vivo admin-
istration of anti-TGF-β antibody in mice implanted with renal 
cell carcinoma reduced tumor burden, decreased numbers of 
circulating FOXP3+ CD25+ CD4+ cells in peripheral blood, 
and removed the immunosuppressive capabilities of FOXP3+ 
CD25+ CD4+ T cells (283). This leaves open the possibility that 
iTregs play an important but poorly understood role in tumor 
immunoresistance. In fact, one murine sarcoma model illustrated 
that intratumoral nTregs and iTregs may collaborate to suppress 
different arms of the adaptive immune response, with nTregs 
preferentially suppressing CD8+ T cells and iTregs suppressing 
CD4+ T cells, respectively (284).
Therapeutic implications
From a therapeutic standpoint, these findings are particularly 
important. Traditional approaches to depleting Tregs, such as 
anti-CD25 antibodies (285) and cyclophosphamide (286), are 
largely non-specific, and whether these strategies preferentially 
target nTreg or iTreg populations is currently unknown (257). 
However, with the current knowledge that nTregs may comprise 
the majority of tumor-infiltrating Tregs in the brain and the body, 
it may be possible to devise targeted depletion strategies for nTregs, 
thereby minimizing side effects associated with indiscriminate 
systemic Treg depletion (258). For example, nTregs are believed to 
exert their immunosuppressive effects predominately via contact-
dependent, cytokine-independent mechanisms (49). These include 
co-stimulatory and co-inhibitory molecules CTLA-4 and PD-L1, 
membrane-bound TGF-β, pericellular generation of adenosine, 
and granzyme B/perforin and Fas/FasL pathways (49, 263–268). 
Therefore, it may be possible to modulate nTreg activity by blocking 
the interactions between these immunosuppressive cell-surface 
ligands and their receptors (287–289).
Blocking Treg recruitment may offer another route for reducing 
intratumor Treg burden in a specific manner. CCL22–CCR4, a 
shared chemokine pathway for Treg migration in several tumors of 
the brain and the body, may prove useful for reducing Treg burden 
in a targeted manner (290). Recently, Adeegbe et  al. reported 
that using anti-CCR4 antibodies in human melanoma patients 
selectively depleted CCR4+ Tregs while sparing naïve Tregs (257). 
Other strategies that interfere with the CCL22–CCR4 axis have 
demonstrated moderate success in in vitro and pre-clinical in vivo 
experiments (290–292).
Finally, within tissues of the body where inflammation pro-
motes carcinogenesis, such as with gastric cancers or colorectal 
carcinoma, greater numbers of Tregs suppress inflammation and 
may therefore have anti-tumor effects. Greater degree of Treg 
tumor infiltration has in fact been associated with better prognosis 
in colorectal cancers (293, 294). Therefore, immunotherapeutic 
strategies that target Treg depletion need to consider the environ-
mental context within which tumorigenesis occurs.
Part vii: Tumor-Associated Myeloid Cells
The role of myeloid-lineage cells in promoting tumor growth 
and invasion has come into focus in recent years. At least five 
distinct subpopulations of tumor-associated myeloid cells 
(TAMCs) have been identified, including monocyte-derived 
tumor-associated macrophages (TAMs); angiogenic monocytes; 
immature, immunosuppressive myelomonocytic cells known 
as MDSCs; tumor-associated neutrophils (TANs); as well as 
microglia within the CNS (87). Their expansive roles in facilitat-
ing immunosuppression, angiogenesis, cellular proliferation, 
and tumor invasion in CNS and non-CNS sites have prompted 
investigations into new immunotherapeutic strategies aimed at 
neutralizing TAMCs. Representative classes of TAMCs as they 
relate to gliomas will be discussed below; an in-depth review of 
TAMCs can be referenced here (87).
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TAMCs in Malignant Gliomas
Microglia and monocyte-derived macrophages (i.e., TAMs) 
together account for the majority of glioma-associated myeloid 
cells (87, 159). Microglia, the resident macrophages of the CNS, 
compose 5–20% of the total glial cell population (84, 85) and play 
an essential role in the innate defense system of the brain (91). 
Monocyte-derived macrophages, by comparison, are normally 
restricted to the perivascular, choroid, and meningeal locations 
of the CNS (see Part II: The CNS Immune Environment), gaining 
entry to the parenchyma only after disease and/or inflammation 
have disrupted the integrity of BBB. In the setting of glioma, TAMs 
and microglia can comprise upward of 30% of the total tumor mass, 
with reports indicating that high-grade gliomas tend to exhibit 
greater levels of TAMs and microglia accumulation than low-grade 
gliomas (87, 295, 296).
Similar to monocyte-derived macrophages, both microglia and 
TAMs can embody pro-inflammatory (M1) as well as immunosup-
pressive (M2) phenotypes depending on environmental cues (99, 
297). In the presence of inflammatory signals, classically activated 
microglia and macrophages skew toward an M1-like phenotype, 
characterized by increased capacity to migrate, phagocytose, 
secrete cytotoxic factors, as well as express MHC class II and 
co-stimulatory molecules for T cell activation (91). In the setting 
of gliomas, however, the data suggest that microglia and TAMs 
polarize toward an M2-like phenotype (91–93), particularly in 
late stages of disease progression (298), and exhibit immunosup-
pressive, pro-invasive properties that facilitate tumor growth. 
It is important to note that the M1/M2 classification is useful 
for illustrating the dichotomous role of microglia and TAMs in 
tumorogenesis but is ultimately an oversimplification, as TAMs 
and microglia exhibit a continuum of phenotypes at any one time, 
and the functional outcome may ultimately hinge upon the balance 
of pro-inflammatory and anti-inflammatory TAMs and microglia 
in the tumor microenvironment (159).
Recent work has produced convincing evidence that microglia 
and TAMs represent distinct classes of mononuclear phagocytic 
cells based on developmental origin (299, 300); however, distin-
guishing between TAMs and microglia in glioma tissue has proved 
difficult. Historically, cell-surface markers, CD11b integrin and 
common leukocyte antigen CD45, have been used to parse the two 
cell populations, with microglia expressing CD11bhigh/CD45low and 
TAMs expressing CD11bhigh/CD45high, but the reliability of these 
markers in practice remains controversial (87). Newer genetic 
techniques employing inducible gene reporters to identify unique 
developmental markers in non-diseased murine models have had 
success in distinguishing monocyte-derived macrophages from 
microglia in vivo (301–303); however, whether such techniques 
can accurately identify macrophages and microglia in the setting 
of glioma remains to be determined. Therefore, the subsequent 
discussion will refer collectively to both macrophage populations 
as glioma-associated microglia and macrophages (GAMs) (304).
Glioma-Associated Microglia and Macrophages
Gliomas recruit GAMs in significant numbers, with GAMs compris-
ing as much as one-third of all tumor-associated inflammatory cells 
(305). GAMs are recruited via glioma-derived chemo-attractants, 
including CCL2 (306), CCL7 (307), CX3CL1 (308), and stromal-
derived factor-1 (SDF-1) (309); GAMs are subsequently sustained 
within tissue via glioma-derived growth factors, such as CSF-1, 
G-CSF, and hepatocyte growth factor (310–312). In exchange for 
pro-growth factors, GAMs provide the tumor with matrix metal-
loproteinases, which facilitate tumor growth and invasion (96), as 
well as tumor proliferation promoting factors, such as epidermal 
growth factor (EGF) (97) and vascular endothelial growth factor 
(VEGF) (98). Under the influence of glioma-associated cytokines, 
GAMs further upregulate immunosuppressive programmed death 
ligand 1 (PD-L1) (94, 95), which promotes T-lymphocyte anergy, 
as well as FASL, which promotes T-lymphocyte apoptosis (313, 
314). Moreover, gliomas induce GAMs to substantially decrease 
the expression of MHC molecules and pro-inflammatory cytokines 
(TNF-α) while increasing the secretion of transcription factor, 
STAT3, likely through S100B-receptor for advanced glycation end 
produces (RAGE) axis (315). GAM STAT3 activation promotes the 
secretion of immunosuppressive cytokines, IL-6 and IL-10, which 
are known to inhibit cytotoxic T lymphocyte function, among 
other immunosuppressive actions (316, 317).
Discoveries surrounding the role of GAMs in promoting tumor 
growth have been followed closely by strategies to modulate their 
immunosuppressive actions. Transcription factor STAT3, which is 
upregulated in glioma-associated microglia, is a promising target 
for molecular intervention. In  vitro blockade of STAT3 using 
siRNA reduced the microglial expression of immunosuppressive 
cytokines, IL-6 and IL-10 (316). In vivo silencing of STAT3 in a 
murine glioma model promoted a pro-inflammatory microglia 
response that inhibited tumor growth (316). Corosolic and 
oleanolic acids, known inhibitors of STAT3, have also been shown 
to reduce the macrophage expression of CD163, a marker of the 
immunosuppressive M2 phenotype, as well as IL-10, suggesting 
that these molecules may hold potential for reversing M2-like 
polarization of microglia (318, 319). Other novel approaches 
include the use of antibodies to block microglia chemotaxis 
toward gliomas, analogous to efforts aimed at attenuating Treg cell 
recruitment. Anti-CCL2 therapy, for example, has shown success 
in prolonging survival in murine glioma models (320). Other novel 
strategies have been well reviewed here (321).
Myeloid-Derived Suppressor Cells in 
Malignant Gliomas
Compared to TAMs and/or microglia, relatively less is known 
about the role of MDSCs in gliomagenesis and progression. 
MDSCs represent a diverse population of immature and highly 
immunosuppressive myeloid cells that accumulate in the tumor, 
blood, lymph nodes, and bone marrow of tumor-bearing hosts 
in response to tumor-derived factors, such as IL-6, IL-10, PGE2, 
TGF-β2, and VEGF (89, 322, 323). Though controversial, MDSCs 
are most commonly classified as either monocytic or granulocytic 
MDSCs (also known as polymorphonuclear MDSCs), with granu-
locytic MDSCs exerting weaker immunosuppression compared to 
monocytic MDSCs on a per cell basis (89). A population of pro-
myelocytic MDSCs, representing an even more immature lineage of 
myeloid suppressor cells that are negative for both monocytic and 
granulocytic markers, has also more recently been described (324).
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It is thought that granulocytic MDSCs suppress antigen-
specific CD8+ T cell activity via production of reactive oxygen 
species (ROS), which, for example, could trigger apoptosis in 
activated T cells by decreasing Bcl-2 expression (325), while 
monocytic MDSCs increase l-arginine metabolism via NO 
and ARG-1 pathways, causing micro-environmental arginine 
depletion, ultimately leading to downregulation of T cell recep-
tor components as well as T cell cell cycle arrest (326–328). 
Additionally, MDSCs are also thought to interfere with T-cell 
trafficking, induce NK- and T-cell anergy, and enhance Treg 
activation and expansion (329). In a study by Raychuadhuri 
et al., T cells isolated from patients with GBM had significantly 
depressed IFN-γ production following stimulation. Subsequent 
depletion of MDSCs from peripheral blood using anti-CD33/
CD15-coated beads significantly restored T cell IFN-γ production 
in vitro (330).
In gliomas, the majority of circulating MDSCs appear to be 
predominately granulocytic (329). Interestingly, Gielen et  al. 
recently reported that while patients with GBM contain elevated 
levels of both granulocytic and monocytic MDSCs in peripheral 
blood when compared to healthy controls, glioma tissues contain 
almost exclusively granulocytic MDSCs (331), a finding that 
may have important implications for MDSC-targeted therapy. In 
addition, the authors reported that patients who had had longer 
courses of dexamethasone for cerebral edema displayed greater 
levels of both classes of MDSCs in peripheral blood, a finding that 
could merely reflect patient-level differences in tumor mass but 
also possibly dexamethasone-mediated alterations to myeloid cell 
phenotypes, warranting further investigation (331). There is also 
compelling data suggesting that circulating MDSCs may arise from 
glioma-associated monocytes. Chae et  al. recently showed that 
mice that received transgenic green fluorescent protein (GFP)+ 
CD11b+ splenic monocytes along with GL261-Luc cells not only 
had shorter survival, faster tumor growth, and higher levels of 
intratumoral and circulating MDSCs compared to mice that 
received GL261-Luc cells alone but also their work showed that 
30–50% of circulating MDSCs were GFP+, suggesting that MDSCs 
arose directly from GFP+ monocytes (332).
Myeloid-derived suppressor cell-targeted immunotherapy is an 
area of active research. For example, various murine glioma models 
have shown that depletion of MDSCs, either via COX-2 inhibi-
tion (278), antibody-mediated MDSC depletion (278), or CCL2 
neutralization (320), can prolong the survival. Other strategies for 
modulating MDSCs have been highlighted here (329).
Tumor-Associated Myeloid Cells  
in Non-CNS Sites
Immunosuppressive myeloid cells are not unique to CNS tumors 
and are equally important facilitators of tumor growth and inva-
sion in peripheral sites as well. Higher density of tumor-associated 
macrophages (TAMs) has been associated with poorer prognosis 
in several human cancers, including breast, prostate, bladder, colo-
rectal, and gastric cancers (333). Increased levels of M2-polarized 
TAMs have been correlated with accelerated metastasis and 
reduced survival in pancreatic (334) and renal cell carcinoma (88) 
as well as certain lymphomas (335). Indeed, several glioma-derived 
chemokine mediators that are important in re-purposing microglia 
with immunosuppressive functions are also implicated in polar-
izing peripheral tumor-associated macrophages toward an M2 
immunosuppressive phenotype (99).
Although the relative distribution of microglia and TAMs in 
gliomas has yet to be fully characterized (see above discussion), 
an intriguing observation that the majority of tumor-infiltrating 
mononuclear phagocytes in murine gliomas may represent 
monocyte-derived macrophages rather than native microglia sug-
gests that monocyte-derived macrophages may play a significant 
role in coordinating glioma growth (86). Immunotherapy aimed 
at modulating macrophage populations in the CNS may therefore 
be highly pertinent to managing immunosuppressive macrophages 
within non-CNS tumors, and vice versa.
Myeloid-derived suppressor cells have also been implicated in 
facilitating local and systemic immunosuppression in the setting of 
non-CNS tumors, including breast, colon, lung, kidney cancer, and 
head-and-neck cancers (89, 90), making MDSC-targeted therapy 
relevant to tumor immunotherapy at all sites. The mechanisms 
by which MDSCs arise and confound anti-tumor immunity, 
however, may differ depending on tumor site. For example, tumor-
conditioned media from certain non-CNS tumors has been shown 
to induce immunosuppressive phenotypes in myeloid cells (322, 
336); however, in vitro data from Rodrigues et al. revealed that 
direct contact between monocytes and glioma cells was needed 
to induce an MDSC-like phenotype in monocytes (90). Moreover, 
Rodrigues et al. failed to find a correlation between serum levels 
of tumor-derived cytokines known to stimulate MDSC prolifera-
tion in patients with gliomas compared to healthy counterparts 
(90), suggesting that the elevated levels of circulating MDSCs 
in patients with gliomas may arise from direct contact between 
tumor-infiltrating macrophages and/or monocytes and glioma 
cells rather than via systemic cytokine-induced conversion. Recent 
work from Chae et al., who showed GFP+ monocytes co-injected 
with GL261 cells into murine brains, led to increased levels of 
GFP+ MDSCs lends credence to the theory (332).
The relative proportions of circulating granulocytic, monocytic, 
and lineage-negative MDSCs may also vary depending on tumor 
type. Compared to patients with melanoma, renal cell carcinoma, 
and bladder carcinoma, patients with GBM had the greatest 
levels of granulocytic MDSCs (330). While the relative distribu-
tion of granulocytic, monocytic, and lineage-negative MDSCs 
in the peripheral blood of patients with renal cell carcinoma 
and bladder cancer appear consistent with that of GBM (i.e., 
granulocytic > lineage-negative > monocytic MDSCs), patients 
with melanoma have nearly equal percentages of granulocytic 
and lineage-negative MDSCs (330). The exact clinical relevance 
of differing proportions of MDSCs in different tumor types has 
yet to be elucidated; however, given that different subclasses of 
MDSCs may utilize different mechanisms of immunosuppression, 
MDSC-targeted immunotherapy may ultimately need to account 
for the predominant subsets of MDSCs associated with various 
tumor types.
Lastly, in keeping with the theme of other immunotherapeutic 
targets discussed in this review, targeting MDSCs may ultimately 
be highly contextual and tumor-dependent. Although depletion 
of MDSCs in certain glioma models has led to survival benefits 
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(278, 320, 337), eliminating MDSCs may produce opposite effect 
in other tumor models. For example, Kerkar et  al. reported 
that IL-12 immunotherapy in a B16 murine melanoma model 
“reprogramed” MDSCs, which in turn actually potentiated the 
anti-tumor effects of CD8+ T cells (338). By comparison, IL-12 
immunotherapy prolonged the survival in a GL261 murine glioma 
model regardless of whether MDSCs were depleted (339), indicat-
ing that MDSCs may play a different supporting role in IL-12 
immunotherapy in melanomas versus gliomas. Further work is 
needed to ascertain the functional outcome of depleting MDSCs in 
different tumor models. Simultaneously, it will also be prudent to 
assess the viability of “reprograming” MDSCs into mature myeloid 
cells that promote tumor elimination, similar to what has been 
accomplished with using all-trans retinoic acid in the treatment 
of acute pro-myelocytic anemia.
Part viii: immune Checkpoints Molecules
Therapeutic modulation of co-stimulatory and co-inhibitory 
receptors of the immune system, often referred to as “immune 
checkpoint molecules,” has erupted in recent years following the 
seminal work in blockading cytotoxic T-lymphocyte antigen 
4 (CTLA-4), a co-inhibitory molecule expressed on activated 
T-cells and Treg cells. Ipililumab, an mAb directed against 
CTLA-4, was the first therapy to procure survival benefits for 
patients with metastatic melanoma (340), providing proof-of-
concept that disrupting checkpoint molecules could alone reverse 
tumor immunoresistance and lead to immune-mediated tumor 
eradication.
Numerous immune checkpoint molecules have subsequently 
been identified (341) and hold substantial promise as targets for 
tumor immunotherapy in the brain and the body. In this regard, 
characterizing immune checkpoint molecule, programmed cell 
death protein-1 ligand (PD-L1), its role in immune regulation, 
and opportunities for therapeutic intervention in the CNS and 
other sites is particularly instructive.
Programmed Cell Death Protein-1 Ligand
Programmed cell death protein-1 ligand (B7-H1, CD274) is a 
trans-membrane glycoprotein of the B7 family of co-stimulatory 
molecules with potent immune-regulatory properties (120, 342). 
Under normal physiological states, PD-L1 is largely restricted to 
myeloid-lineage cells, including DCs and macrophages (343), 
and binds its receptor, programmed cell death protein-1 (PD-1, 
CD279), which is predominately expressed on activated T-cells 
(342, 344). Activation of PD-1 suppresses proliferation and lytic 
functions of effector T cells while expanding immunosuppres-
sive Treg cells (341). Under inflammatory states, PD-L1/PD-1 
signaling protects against rampant T cell activation and autoim-
munity. Numerous tumors in the brain and the body, however, 
also express PD-L1, which can suppress tumor-directed cytotoxic 
T-cells that would otherwise destroy it (341). PD-L1 expression 
in several tumors, including renal cell carcinoma (105, 106), lung 
carcinoma (107, 108), breast carcinoma (109), and glioblastoma 
(119), has been correlated with higher tumor grade and poorer 
prognosis (120).
PD-L1: Malignant Gliomas
Aside from endothelial cells of the BBB, PD-L1 is usually not 
expressed in the CNS (345–347), and PD-L1 expression on glial 
cells and/or neurons is typically signs of pathological states. In 
gliomas, PD-L1 expression is positively correlated with malig-
nancy grade (205) and is likely driven by genetic alterations that 
also potentiate oncogenesis. Loss of PTEN tumor suppressor gene 
enhances the expression of PD-L1 on glioma cells, suggesting 
that activation of PI(3)K-Akt-mammalian target of rapamycin 
(mTOR) pathway may modulate PD-L1 translation (101). 
Concurrently, greater degrees of PD-1 expression on peripheral 
CD4+ and CD8+ T cells are also observed in gliomas of higher 
malignant grade (119), and co-culturing alloreactive CD4+ and 
CD8+ T cells with PD-L1-expressing glioma cells significantly 
depresses the production of inflammatory cytokines, such as IFN-
γ and IL-2 (118). Accordingly, the PD-1/PD-L1 axis has become 
an attractive target for glioma immunotherapy. Blocking PD-L1 
on glioma cells with mAbs in combination with radiotherapy 
has yielded particularly potent survival benefits in pre-clinical 
models (348).
In addition to glioma cells, TAMCs provide another source 
of PD-L1. Microglia are known to upregulate PD-L1 expression 
under inflammatory states (94), and microglial expression of 
PD-L1 has indeed been reported in human glioblastoma tissue 
(102). Recently, Parsa et  al. reported that gliomas also induce 
PD-L1 expression on tumor-infiltrating macrophages, which may 
further contribute to PD-1-mediated T-cell suppression (103). This 
finding is particularly compelling, as it provides a cellular basis 
by which gliomas may induce global immunosuppression via 
monocyte-derived macrophages. Whether the benefits observed 
from anti-PD-L1 mAbs are due primarily to blocking PD-L1 
expressed by gliomas, TAMs, microglia, or combinations thereof, 
remains to be determined.
Notably, in the first study that extensively characterized the role 
of neurons in the GBM microenvironment in inhibiting tumor 
growth, Liu et  al. reported that high levels of neuronal PD-L1 
expression in tumor-adjacent brain tissue (TABT) corresponded 
favorably with overall patient survival, and low TABT PD-L1 
expression and high GBM PD-L1 expression portended poorer 
patient survival (104). Mechanistic analysis revealed neurons 
expressing PD-L1-induced caspase-mediated apoptosis of GBM 
cells (104). Neuronal expression of IFN-β, which enhances neu-
ronal expression of PD-L1, was also postulated to suppress glioma 
growth via its tumor-suppressor functions (104). These findings 
illuminate the potential drawbacks of indiscriminate administra-
tion of PD-L1 neutralizing antibodies, which might limit native 
host neuron defenses against gliomagenesis.
PD-L1: Non-CNS Tumors and  
implications for Therapy
The biological pathways implicated in enhancing PD-L1 expres-
sion in gliomas are equally important to the development of 
immunoresistance in tumors outside of the CNS. Expression of 
PD-L1 on colorectal carcinomas, for example, has also been linked 
to loss of PTEN tumor suppressor (349). Similarly, PI3K/mTOR 
pathway activation is also associated with PD-L1 expression in 
July 2015 | Volume 5 | Article 15315
Perng and Lim Tumor immunosuppression: gliomas, non-CNS sites
Frontiers in Oncology | www.frontiersin.org
breast (115), lung (108), renal cell (106), and prostate carcinomas 
(116). Molecular therapies targeting these pathways are therefore 
relevant to all of these tumors.
At the same time, other malignancies also utilize distinct signal-
ing pathways to enhance PD-L1 expression, requiring that targeted 
molecular suppression of PD-L1 be tailored toward each site based 
on tumor-specific biology. For example, MyD88/TRAF6 and MEK/
ERK pathways enhance PD-L1 expression in multiple myeloma 
(117), while constitutive activation of anaplastic lymphoma kinase 
(ALK) drives PD-L1 expression in certain lymphomas and lung 
carcinomas (341, 350).
Targeting the PD-L1/PD-1 axis by indirectly modulating PD-L1-
bearing TAMs may also prove to be relevant strategy for CNS and 
non-CNS tumors alike (100, 110). Hepatocellular carcinomas, like 
gliomas, also recruit high numbers of PD-L1-expressing TAMs 
into the tumor microenvironment, corresponding with poor 
prognosis (111).
Lastly, the astonishing discovery that neuronal expression of 
PD-L1 in the tumor microenvironment protects against gliom-
agenesis (104) may also find parallels in the body. Pancreatic, heart, 
endothelial, small intestine (112), and placental tissues (113) also 
express PD-L1 (114). Whether tissue expression of PD-L1 at sites 
outside of the CNS similarly protects against local tumorogenesis 
remains an open question.
Beyond PD-L1
Beyond PD-L1, effector immune cells express myriad checkpoint 
molecules that also contribute tumor immunoresistance both 
in brain and body. Targeting cytotoxic T-lymphocyte antigen 4 
(CTLA-4), which modulates early stages of T-lymphocyte activa-
tion, has proved useful in reversing immunoresistance in gliomas, 
as it has in non-CNS tumors (351–355). In an experimental 
glioma model, anti-CTLA-4 mAb procured an 80% long-term 
survival rate, concurrent with enhanced proliferation of CD4+ 
CD25− T cells and resistance to suppression by Treg cells (351). 
Glucocorticoid-induced tumor necrosis factor receptor-related 
gene (GITR) has emerged as an important checkpoint molecule 
in Treg cells (356). Additionally, Tim-3 (357) and 4-1BB (CD137) 
(358) are other key immune checkpoint molecules that will also 
require site-specific considerations, especially as immunothera-
peutic strategies develop to target these ligands individually and 
in combination (68).
Part iX: Concluding Remarks
A major challenge for the field of brain tumor immunology lies 
in elucidating key determinants and constituents of the pro-
inflammatory and anti-inflammatory responses in the CNS such 
that they might be augmented for therapeutic gain. Contrary to 
the historical view of the CNS as immunologically sequestered 
from the rest of the body, the immune responses in the CNS are 
linked and complementary to immune processes in the periph-
ery. The phenotype of the immune response often hinges upon 
cytokines and cellular mediators that exert highly pleiotropic 
and sometimes paradoxical actions depending on the specific 
tumor and environmental context. In evaluating these processes, 
however, it will be helpful to recognize that routes by which the 
CNS coordinates immune modulation are not without precedent: 
analogous immunological mechanisms exist at sites outside of 
the CNS, and advances in tumor immunotherapy in peripheral 
sites may therefore illuminate novel approaches to brain tumor 
immunotherapy, and vice versa (1). Therefore, this suggests that the 
intricacies of the brain immune environment need to be examined 
within the context of the entire body.
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